An Italian case series' description of thiamine responsive megaloblastic anemia syndrome: importance of early diagnosis and treatment.
Case series
Nonautoimmune diabetes
Optic atrophy
Sensorineural deafness
Thiamine-responsive megaloblastic anemia syndrome
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
01
08
2023
accepted:
12
09
2023
medline:
4
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
Individuals with thiamine-responsive megaloblastic anemia (TRMA) mainly manifest macrocytic anemia, sensorineural deafness, ocular complications, and nonautoimmune diabetes. Macrocytic anemia and diabetes may be responsive to high-dosage thiamine treatment, in contrast to sensorineural deafness. Little is known about the efficacy of thiamine treatment on ocular manifestations. Our objective is to report data from four Italian TRMA patients: in Cases 1, 2 and 3, the diagnosis of TRMA was made at 9, 14 and 27 months. In 3 out of 4 subjects, thiamine therapy allowed both normalization of hyperglycemia, with consequent insulin suspension, and macrocytic anemia. In all Cases, thiamine therapy did not resolve the clinical manifestation of deafness. In Cases 2 and 3, follow-up showed no blindness, unlike Case 4, in which treatment was started for megaloblastic anemia at age 7 but was increased to high doses only at age 25, when the genetic diagnosis of TRMA was performed. Early institution of high-dose thiamine supplementation seems to prevent the development of retinal changes and optic atrophy in TRMA patients. The spectrum of clinical manifestations is broad, and it is important to describe known Cases to gain a better understanding of this rare disease.
Sections du résumé
BACKGROUND
BACKGROUND
Individuals with thiamine-responsive megaloblastic anemia (TRMA) mainly manifest macrocytic anemia, sensorineural deafness, ocular complications, and nonautoimmune diabetes. Macrocytic anemia and diabetes may be responsive to high-dosage thiamine treatment, in contrast to sensorineural deafness. Little is known about the efficacy of thiamine treatment on ocular manifestations.
CASES PRESENTATION
METHODS
Our objective is to report data from four Italian TRMA patients: in Cases 1, 2 and 3, the diagnosis of TRMA was made at 9, 14 and 27 months. In 3 out of 4 subjects, thiamine therapy allowed both normalization of hyperglycemia, with consequent insulin suspension, and macrocytic anemia. In all Cases, thiamine therapy did not resolve the clinical manifestation of deafness. In Cases 2 and 3, follow-up showed no blindness, unlike Case 4, in which treatment was started for megaloblastic anemia at age 7 but was increased to high doses only at age 25, when the genetic diagnosis of TRMA was performed.
CONCLUSIONS
CONCLUSIONS
Early institution of high-dose thiamine supplementation seems to prevent the development of retinal changes and optic atrophy in TRMA patients. The spectrum of clinical manifestations is broad, and it is important to describe known Cases to gain a better understanding of this rare disease.
Identifiants
pubmed: 38037112
doi: 10.1186/s13052-023-01553-1
pii: 10.1186/s13052-023-01553-1
pmc: PMC10691017
doi:
Substances chimiques
Thiamine
X66NSO3N35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
158Informations de copyright
© 2023. The Author(s).
Références
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
J Inherit Metab Dis. 1984;7 Suppl 2:153-4
pubmed: 6090807
Diabetologia. 2018 May;61(5):1027-1036
pubmed: 29450569
J Pediatr. 1969 Apr;74(4):494-504
pubmed: 5767338
Int J Lab Hematol. 2022 Aug;44(4):e175-e178
pubmed: 35355416
J Inherit Metab Dis. 1992;15(2):231-42
pubmed: 1326679
Curr Mol Med. 2001 May;1(2):197-207
pubmed: 11899071
J Clin Invest. 1999 Mar;103(5):723-9
pubmed: 10074490
Panminerva Med. 2002 Dec;44(4):295-300
pubmed: 12434122
Int J Environ Res Public Health. 2022 Jan 12;19(2):
pubmed: 35055657
Diagnostics (Basel). 2021 Jun 25;11(7):
pubmed: 34202200
J Pediatr. 2009 Dec;155(6):888-892.e1
pubmed: 19643445
Pediatr Diabetes. 2012 Jun;13(4):314-21
pubmed: 22369132
J Clin Res Pediatr Endocrinol. 2011;3(1):36-9
pubmed: 21448333
Pediatr Cardiol. 2003 Sep-Oct;24(5):476-81
pubmed: 14627317
Front Pediatr. 2021 Apr 29;9:661434
pubmed: 33996696
Hum Mutat. 2000;16(1):37-42
pubmed: 10874303
Clin Chim Acta. 2021 May;516:157-168
pubmed: 33571483
Diabetes Res Clin Pract. 2022 Jan;183:109154
pubmed: 34826540
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Pediatr Diabetes. 2013 Aug;14(5):384-7
pubmed: 23289844
J Pediatr. 1989 Mar;114(3):405-10
pubmed: 2537896
Turk J Pediatr. 2018;60(3):348-351
pubmed: 30511554
Diabetes Care. 1998 Jan;21(1):38-41
pubmed: 9538968